A61P 7 - Drugs for disorders of the blood or the extracellular fluid

Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
10/2002
10/31/2002	US20020160481 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
10/31/2002	US20020160478 Short peptides which selectively modulate the activity of protein kinases
10/31/2002	US20020160059 Treatment of urogenital disorders, menstrual cramps
10/31/2002	US20020160015 Chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes and its uses
10/31/2002	US20020159996 Use of CD23 antagonists for the treatment of neoplastic disorders
10/31/2002	US20020159978 RAAV virion(recominant adeno-associated virus) comprising an AAV-6 capsid, and a heterologous nucleic acid encoding Factor IX operably linked to expression control element, administering virion to a muscle cell
10/31/2002	US20020159977 Administering a recombinant adeno-associated virion into human suffering from hemophilia such that factor VIII nuclotide sequence are expressed at a level which provide therapeutically effective amount in the patient
10/31/2002	US20020159951 Administering to the patient a contrast agent comprising, in an aqueous carrier, targeted vesicles formulated from a lipid or polymer, a prfluorocarbon gas, a targeting ligand, scanning the patient using ultrasound to obtain an image
10/31/2002	CA2445233A1 Phthalazinones derivatives useful as pde4/7 inhibitors
10/31/2002	CA2445188A1 Arylindenopyridines with pde inhibiting activity
10/31/2002	CA2445160A1 Coumarin derivatives to be used as anticoagulants
10/31/2002	CA2445071A1 Oligonucleotide compositions and their use to induce differentiation of cells
10/31/2002	CA2444675A1 Secreted proteins
10/31/2002	CA2444599A1 Melanocortin receptor ligands
10/31/2002	CA2444571A1 1, 4, 5, 6-tetrahydropyrazolo-¬3, 4-c\|-pyridin-7-ones as factor xa inhi bitors
10/31/2002	CA2444370A1 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002	CA2444235A1 New polynucleotides and polypeptides of the ifn.alpha.-17 gene
10/31/2002	CA2444098A1 Methods and compositions for the production of orthogonal trna-aminoacyl trna synthetase pairs
10/31/2002	CA2443936A1 Use of ppar-alpha-gamma ligands or agonists to prevent the rupture of atherosclerotic plaques
10/31/2002	CA2443757A1 In vivo incorporation of unnatural amino acids
10/31/2002	CA2443600A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002	CA2443373A1 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002	CA2442112A1 Use of creatine for the amelioration of oxidative stress
10/31/2002	CA2441772A1 1,4,5,6-tetrahydropyrazolo-¬3,4-c\|-pyridin-7-ones as factor xa inhibitors
10/30/2002	EP1253142A1 Compounds exhibiting thrombopoietin receptor agonism
10/30/2002	EP1252883A1 Process for reducing partially or completely the symptoms associated with the histamin release within the human body
10/30/2002	EP1252333A2 Methods and materials relating to cd84-like polypeptides and polynucleotides
10/30/2002	EP1252313A2 Use of dendroaspin as a vehicle for non-dendroaspin domains
10/30/2002	EP1252177A1 Ligand for vascular endothelial growth factor receptor
10/30/2002	EP1252164A1 Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid
10/30/2002	EP1252158A1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
10/30/2002	EP1252157A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
10/30/2002	EP1252144A1 Substituted glutarimides and use thereof il-12 production inhibitors
10/30/2002	EP1252137A1 Palatable arginine compounds and uses thereof for cardiovascular health
10/30/2002	EP1252133A2 Pharmaceutical compounds
10/30/2002	EP1251864A1 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
10/30/2002	EP1251829A1 Electrospun pharmaceutical compositions
10/30/2002	EP0852225B1 Fibrinogen receptor antagonists and medicinal preparations containing the same as the active ingredient
10/30/2002	EP0763061B1 Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments
10/30/2002	EP0689449B1 Therapeutical compositions for use in humans, characterised by a combination of a muramyl peptide and a cytokine
10/30/2002	CN1377408A The PRV-1 gene and use thereof
10/30/2002	CN1377356A Certain alkylene diamine-substituted heterocycles
10/30/2002	CN1377355A Amino substituted pyrazolo [1,5-2]-1,5-pyrimidines and pyrazolo [1,5-2]-1,3, 5-triazines
10/30/2002	CN1377346A Z-pyrazoline-5-ones
10/30/2002	CN1377277A Use of leptin in inhibition of endothelial cell proliferation
10/30/2002	CN1377266A Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion
10/30/2002	CN1376667A Medical compound with antalgic, inflammation relieving and thrombocyte decoagulating actions
10/30/2002	CN1376472A Medicine for treating aplastic anemia and its preapring process
10/29/2002	US6472562 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
10/29/2002	US6472412 Compounds as PDE IV and TNF inhibitors
10/29/2002	US6472405 Glycoprotein IIB/IIIA antagonists
10/29/2002	US6472399 Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
10/29/2002	US6472393 Serine protease inhibitors
10/29/2002	US6472390 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
10/29/2002	US6472212 Methods and compositions for genetically modifying primate bone marrow cells
10/29/2002	US6472200 In vivo organ architecture (organ structure) of organ units (e.g., acinus of liver) is maintained within each indivisual micro-organ culture and the cultures being loacted within the chamber, in contact with fluid flowing through chamber
10/29/2002	US6472162 Obtaining blood from a patient, sequestering plasma, adding ethanol in a concentration fo 8-20% to prepare a solution containing prothrombin, converting to thrombin, filtering and applying to a patient
10/29/2002	US6471978 Localized use of nitric oxide-adducts to prevent internal tissue damage
10/29/2002	US6471968 Multifunctional nanodevice platform
10/29/2002	EP1144613A4 Methods for making proteins containing free cysteine residues
10/29/2002	CA2088128C Salts of glucopyranose derivatives and its intermediate
10/28/2002	EP1009417A4 Dietary supplements containing natural ingredients
10/24/2002	WO2002084298A2 Medicaments which are modulators of hm74 and/or hm74a activity
10/24/2002	WO2002083879A2 Immunotherapy based on dendritic cells
10/24/2002	WO2002083873A2 Enzymes
10/24/2002	WO2002083841A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/24/2002	WO2002083736A2 G-protein coupled receptor molecules and uses thereof
10/24/2002	WO2002083712A2 Transporters and ion channels
10/24/2002	WO2002083709A2 Kinases and phosphatases
10/24/2002	WO2002083696A2 Novel cyclo azaphospha hydrocarbons
10/24/2002	WO2002083684A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepi ne-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083681A1 Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
10/24/2002	WO2002083680A1 Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
10/24/2002	WO2002083668A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	WO2002083667A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	WO2002083664A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083663A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083643A1 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
10/24/2002	WO2002083627A2 Ligands des integrins avss6
10/24/2002	WO2002083158A1 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles
10/24/2002	WO2002083157A1 Blood group-free human blood plasma and the preparation method thereof
10/24/2002	WO2002083152A1 Activation of natural killer cells by adenosine a3 receptor agonists
10/24/2002	WO2002083147A1 Use of bile acid or bile salt fatty acid conjugates
10/24/2002	WO2002083143A1 Cxcr3 antagonists
10/24/2002	WO2002083120A2 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
10/24/2002	WO2002083103A2 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	WO2002066035A3 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
10/24/2002	WO2002060931A3 A fimbria-like gene in bifidobacteria
10/24/2002	WO2002057226A9 68730 and 69112 protein kinase molecules and uses therefor
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2002003972A3 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
10/24/2002	WO2001077375A8 Diagnosis of diseases associated with gene regulation
10/24/2002	WO2001059103A9 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
10/24/2002	WO2001047529A3 Association of deoxyfructosazine and an antidiabetic agonist of the peroxysome proliferator gamma-activated receptor
10/24/2002	US20020156498 Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same
10/24/2002	US20020156421 Indwelling heat exchange catheter and method of using same
10/24/2002	US20020156266 Sodium phosphate cotransporter expressed on apical surface of intestinal epithelial cells (huNpt2B) and polypeptides related thereto
10/24/2002	US20020156264 And method of using the carboxypeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in carboxypeptidase-related disorders
10/24/2002	US20020156254 Nucleotide sequences coding polypeptide for use in the treatment of stress, diabetes, cancer, inflammatory and cardiovascular disorders
10/24/2002	US20020156104 Novel pyrazole and pyrazoline substituted compounds

1 ... 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 ... 671